Citation:Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al 2012

From Cancer Guidelines Wiki

Citation


Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012 Jul 12;367(2):107-14 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22663011.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Does systemic drug therapy improve progression-free, overall survival in unresectable stage III and stage IV melanoma?Meghna Kakanicompleted
Does systemic drug therapy improve progression-free, overall survival in unresectable stage III and stage IV melanoma?Cecilia Taingcompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Targeted therapies for melanoma